Jeeva Clinical Trials Acquires Clintelligence AI to Transform Clinical Trial Design and Reduce Development Failures
核心洞察
Jeeva Clinical Trials (搜索) acquired Clintelligence (搜索) AI, an artificial intelligence platform that analyzes over one million historical clinical studies to predict trial risks and optimize protocol design.
The acquisition addresses critical industry inefficiencies, with 85% of trials experiencing delays and 30% failing predictably, often due to preventable design flaws that cost upwards of $500,000 per protocol amendment.
Clintelligence (搜索) demonstrates up to 85% accuracy in predicting trial risks and delivers average savings of approximately $350,000 per study through AI-powered protocol optimization and patient matching capabilities.
Jeeva Clinical Trials (搜索) announced the acquisition of Clintelligence (搜索), an AI-powered clinical trial intelligence platform that analyzes insights from over one million historical studies. This strategic acquisition expands Jeeva's Unified AI-Ready Clinical Platform by introducing predictive intelligence capabilities at the earliest stages of clinical development, where trial success or failure is often determined.
The acquisition addresses persistent inefficiencies in clinical development, where approximately 85% of trials experience delays, more than half require protocol amendments, and nearly one-third terminate early due to avoidable design and recruitment challenges. Each protocol amendment can cost upwards of $500,000 and add months to study timelines.
"The biggest inefficiencies in clinical trials are not just operational, they are foundational," said Harsha K. Rajasimha (搜索), PhD, Founder and CEO of Jeeva Clinical Trials (搜索). "Protocol complexity and suboptimal design remain the leading drivers of delays, amendments, and trial failures. Clintelligence (搜索) brings predictive intelligence to the front of the lifecycle, enabling sponsors to identify risks early, optimize design, and move forward with confidence."
AI-Powered Protocol Optimization
Clintelligence (搜索) applies artificial intelligence to a large database of historical clinical trials, delivering predictive insights that help sponsors avoid common pitfalls before a trial begins. The platform has demonstrated up to 85% accuracy in predicting trial risks and delivers average savings of approximately $350,000 per study.
"30% of clinical trials fail predictably and 85% are delayed–but those failures and delays are often preventable," said Agam Bansal (搜索), MD, MS, Founder of Clintelligence (搜索). "Our mission at Clintelligence is to use the power of AI to learn from historical trials' outcomes data and avoid costly mistakes."
The platform enables sponsors to analyze draft protocols against patterns derived from more than one million past studies, predicting amendment likelihood, enrollment delays, and termination risks while providing actionable recommendations to simplify eligibility criteria, refine endpoints, and improve operational feasibility.
Enhanced Patient Recruitment Capabilities
Patient recruitment remains one of the most persistent challenges in clinical trials, with fewer than 5% of eligible patients participating in studies. Clintelligence (搜索) addresses this gap with an AI-powered patient-to-trial matching engine that allows patients to search for trials using natural language.
The system generates eligibility-based screening questions and delivers ranked matches with clear explanations, helping patients and providers identify relevant trials more efficiently. Combined with Jeeva's TrialMagnet recruitment and engagement platform, sponsors gain an integrated pipeline from patient identification through digital enrollment and ePRO data collection.
Site Intelligence and Feasibility Analysis
Clintelligence (搜索)'s site intelligence capabilities profile more than 50,000 research sites across 150+ countries, ranking them based on historical enrollment performance, therapeutic expertise, and competitive saturation. Machine learning-driven forecasting tools provide enrollment projections with confidence intervals and scenario modeling, allowing sponsors to evaluate trial feasibility in minutes rather than months.
Quantifiable Impact on Clinical Development
The integration of Clintelligence (搜索) into Jeeva's platform delivers measurable benefits across the clinical development lifecycle:
- Savings of more than $500,000 per avoided protocol amendment
- Reduction in costly delays, estimated at approximately $37,000 per day
- Acceleration of patient enrollment by 15-20%
- Average savings of $350,000 per trial
- Up to 70% reduction in manual operational burden through automation
Unified Platform Approach
The acquisition strengthens Jeeva's position as a comprehensive, end-to-end clinical trial platform. Jeeva now integrates pre-trial intelligence, patient recruitment, eConsent, visit scheduling, electronic data capture (EDC), electronic patient-reported outcomes (ePRO), real-time monitoring, and analytics into a single interconnected system.
This unified approach eliminates the need for multiple disconnected tools, enabling sponsors, contract research organizations (CROs), and research sites to operate more efficiently with one login, one data model, and one subscription.
"Our customers consistently tell us they want fewer vendors and more integrated solutions," added Rajasimha. "Clintelligence (搜索) significantly enhances our ability to deliver a unified platform that not only executes trials efficiently but also ensures they are designed for success from the start."
With Clintelligence (搜索) integrated into Jeeva's platform, sponsors can now design, optimize, and execute clinical trials within a single, interconnected system from protocol development through patient enrollment, data capture, and study completion.